NCT05411744

One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

Active, enrolled Phase 4 Last updated 21 January 2026

What this trial tests

Phase 4 trial testing 1 month Rifapentine, Isoniazid and Vitamin B6 in Latent Tuberculosis in 25 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 July 2022

Primary endpoint
16 January 2026

30 June 2029

Quick facts

Lead sponsor	Rutgers, The State University of New Jersey
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 July 2022
Primary completion	16 January 2026
Estimated completion	30 June 2029
Sites	1 location across United States

Drugs / interventions tested

• 1 month Rifapentine, Isoniazid and Vitamin B6 — full drug profile →

Conditions studied

• Latent Tuberculosis — all drugs for Latent Tuberculosis →
• End Stage Renal Disease — all drugs for End Stage Renal Disease →
• Renal Transplant Candidate for Right Kidney — all drugs for Renal Transplant Candidate for Right Kidney →
• Renal Transplant Candidate for Left Kidney — all drugs for Renal Transplant Candidate for Left Kidney →

Sponsor

Rutgers, The State University of New Jersey

Who can join

Adults 18 to 90, any sex, with Latent Tuberculosis or End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.